Open AccessShould we Address Biochemical Recurrence of Prostate Cancer as Soon as Possible? Against
Author(s) -
Robert W. Chandler,
Antonella Petremolo,
Pasquale Rescigno,
Johann S. de Bono
Publication year - 2018
Publication title -
european oncology and haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.116
H-Index - 6
eISSN - 2045-5283
pISSN - 2045-5275
DOI - 10.17925/eoh.2018.14.1.14
Subject(s) - medicine , prostate cancer , intervention (counseling) , disease , harm , cancer , stage (stratigraphy) , population , oncology , intensive care medicine , environmental health , nursing , paleontology , political science , law , biology
The advent of enhanced imaging in prostate cancer has resulted in recurrent disease being identified earlier. This has led to an increase in the number of patients undergoing intervention at this early stage. There remains, however, a paucity of level one evidence to advise on the optimal management of this heterogenous group, with a significant number of patients experiencing biochemical relapse unlikely to die of metastatic prostate cancer. More work is needed to define those who do and do not require intervention, to avoid doing harm to an often elderly population.